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 Metastatic Leydig cell tumors are rare and difficult to treat malignancies without known 
underlying molecular-genetic events. 
 We identified TERT gene fusions exclusively in malignant, metastatic Leydig cell tumors.  
 Additional predictive biomarkers (TOP1 and AR) may help guide decisions on chemo- 
and/or hormone therapy for selected individual patients. 
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Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known 
underlying molecular-genetic events. We profiled 27 LCT cases using NGS and 
immunohistochemistry. Our study identified TERT gene fusions as a main genetic alteration and 
a potential therapeutic target in LCT. TOP1 and AR expressions may guide decisions on chemo- 
and/or hormone therapy for selected individual patients. 
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Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without 
known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-
TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was 
then followed by an investigation into a cohort of additional LCTs.  
Patients and Methods: Twenty-nine LCT (27 male and 2 female patients) were profiled using 
NGS and immunohistochemistry.  
Results: TERT gene fusions were detected only in testicular metastatic Leydig cell tumors, in 
three of seven successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT). TOP1 
and CCND3 amplifications were identified in the case with a B4GALT5:TERT fusion. A TP53 
mutation was detected in one metastatic tumor without a TERT fusion. Five primary (four 
testicular and one ovarian) LCTs showed multiple gene amplifications, without a consistent 
pattern. A single metastatic ovarian LCT showed BAP1 mutation and copy number 
amplifications affecting the NPM1, PCM1 and SS18 genes. At the protein level, 4/7 metastatic 
and 6/10 primary testicular LCTs over-expressed TOP1. Androgen receptor (AR) was 
overexpressed in 10/13 primary testicular tumors and 2/5 metastatic testicular LCT (without 
detectable ARv7 mRNA or ARv7 protein). Only one metastatic testicular LCT exhibited high TMB 
while all tested cases were MSI stable and did not express PD-L1.  
Conclusions: Our study for the first time identified TERT gene fusions as a main genetic 
alteration and a potential therapeutic target in metastatic Leydig cell tumors. TOP1 and AR may 
guide decisions on chemo- and/or hormone therapy for selected individual patients. 
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 Sex cord–stromal tumors are an uncommon group of neoplasms affecting gonads. In 
testis, these tumors represent 4% of all neoplasms and are the second largest group of primary 
tumors after germ cell tumors 1. In ovary, sex cord-stromal tumors constitute 5% of all 
neoplasms while 7% of malignant ovarian neoplasms belong to this group 2. Leydig cell tumors 
(LCT) are the most common pure form of sex cord-stromal tumor followed by Sertoli cell, 
granulosa cell, and pure stromal tumors 1. Little is known about the pathogenesis of these 
neoplasms beyond their rare association with germline fumarate hydratase (FH) mutations 
[hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC), OMIM#150800] or the 
activating mutations that affect luteinizing hormone receptor (LHR) in the pediatric population 
1. In addition, DICER1 mutations have been reported in sporadic and hereditary ovarian sex cord 
stromal tumors 3-6. DICER1 gene mutations have been implicated in the dysregulation of the 
steroid hormone synthesis including androgen (AR)7.  
 Molecular profiling studies on these tumors are sparse due to the overwhelmingly 
benign course of the disease and curative surgical resection 8. A recent whole exome 
sequencing study of Yuan et al. revealed that LCTs frequently harbor somatic mutations of 
CDC27 (53%), DICER1 (21%), and MUC22 (21%) genes 8. Metastatic LCTs are clinically 
challenging and without a consensus treatment approach.  
 We have previously characterized multiple cancers using comprehensive molecular 
profiling approach that utilizes various molecular techniques for the identification of potentially 
targetable biomarkers9-13. Our initial case of metastatic LCT showed an LDLR:TERT gene fusion 
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upon routine genetic profiling for detection of therapeutic targets. This led us to investigate a 
cohort of additional LCTs.  
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Materials and Methods 
Samples for the study 
 Twenty-nine LCTs from five participating institutions (listed in affiliations#1, 3, 4, 5, 7 
and 7) were included in the current study.  
 Prior to molecular testing, each LCT case underwent confirmation of the histological 
diagnosis and a review of the diagnostic immunohistochemical work-up performed at the 
referring/participating pathology laboratories. For the study, all histopathological reports and 
remnant LCT tissue samples provided by the referring laboratories and participating institutions 
were de-identified. Based on this, the study was compliant with 45 CFR 46.101(b) and was 
deemed exempt from Institutional Review Board (IRB) approval and consent requirements 
were waived.  
 All molecular assays were performed at a CLIA/CAP/ISO15189/NYSDOH certified clinical 
laboratory (Caris Life Sciences, Phoenix, AZ). 
Immunohistochemistry (IHC) 
 PD‐L1 expression was assessed in the tumor (TC) and immune cells (IC) using SP142 
antibody (Ventana). PD‐L1 expression was considered positive if either TC or IC exhibited any 
membranous/cytoplasmic staining 11, 14. Androgen receptor (AR; clone 441, Leica Biosystems, 
Buffalo Grove, IL) was analyzed using a ≥10% threshold for nuclear positivity 12-14. The ARv7 
splice variant was explored at the protein level by IHC (EPR15656; Abcam) and at the mRNA 
level using anchored multiplex PCR for targeted RNA sequencing (ArcherDX) 9, 11. 
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Topoisomerase 1 (TOP1) expression (clone 1D6, Leica Biosystems, Germany) was scored as 0+, 
1+, 2+, or 3+ depending on the staining intensity, and the percent tumor stained was also 
recorded. The threshold for TOPO1 overexpression was a staining intensity of ≥2+ in ≥30% of 
cancer cells 15.  
Next-generation sequencing (NGS) 
 The LCT samples were profiled using next-generation sequencing (NGS) of exons from 
592 genes (SureSelect XT, Agilent, Santa Clara, CA and the NextSeq instrument, Illumina, San 
Diego, CA). A full gene panel is available in the Supplemental Table 1. 
 The tumor mutational burden (TMB) was assessed by calculating the number of non-
synonymous missense mutations, excluding common germline variants, per one megabase of 
DNA. TMB was considered high if ≥10 mutations/megabase (muts/Mb) were detected 16.  
 Microsatellite instability (MSI) was calculated from the NGS data by direct analysis of 
short tandem repeat tracts in the target regions of sequenced genes. The count only included 
alterations that resulted in increases or decreases in the number of repeats; high microsatellite 
instability (MSI-H) was defined as ≥46 altered microsatellite loci. This threshold was established 
by comparing NGS with the PCR-based microsatellite fragments analysis results from ~2100 
samples 10.  
 Copy number amplifications (CNAs) were assessed by comparing the depth of detected 
NGS sequence reads to calibrated control values. Genes having ≥ six copies were considered 
amplified. 
         
11 
 
 The ArcherDx FusionPlex Assay (ArcherDX, Boulder, CO) was used for gene fusion 
assessment. The gene fusions panel (n=54) is available in the Supplemental Table 2. 
 
  




Clinicopathological characteristics of the cohort 
 Twenty-seven testicular (Seven metastatic and twenty primary tumors) and two ovarian 
LCT (One metastatic and one primary) were investigated. The mean age was 55.5 years (range, 
23-94 years) for male patients; the two female patients with ovarian LCT were 45 and 69 years, 
respectively. The metastatic sites of testicular LCT included lung, liver, mediastinum, 
parasternal region and retroperitoneum (x3). The only ovarian metastatic LCT site was 
peritoneum (four years following the original ovarian tumor diagnosis). 
Immunohistochemical biomarkers 
 Topoisomerase 1 (TOP1) was assessed in 17 testicular LCT: 6 of 10 primary (60%) and 
four of 7 metastatic (57%) LCT were positive (Table 1 and Figure 1). Intriguingly, a single TOP1 
amplified testicular LCT showed no TOP1 protein expression by IHC. AR expression was more 
prevalent among the primary testicular LCT (10/13) compared with the metastatic cases (2/5). 
All cases were ARv7 negative (at either mRNA or protein levels). 
Genomic characteristics of LCT 
 TERT (Telomerase Reverse Transcriptase) gene fusions were exclusively seen in three of 
seven successfully analyzed metastatic testicular LCT. The following fusions were detected: 
RMST:TERT, LDLR:TERT and B4GALT5:TERT (Figure 2). The specimen harboring the 
B4GALT5:TERT fusion also showed amplifications (>6 copies) of the TOP1 and CCND3 genes 
(Table 1). Neither of the two ovarian LCT harbored TERT related fusions. TERT promoter 
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mutations were not tested, because this region was not covered in the available commercial 
NGS panel at the time. 
 A next generation sequencing mutational profile was available for 15 testicular cases, 
which showed inconsistent and rare pathogenic mutations: two primary LCT harbored CTNNB1 
gene mutations (encoding beta-catenin protein); FOXO4 mutations were also observed in two 
cases (one primary and one metastatic case) while a TP53 mutation was observed in one 
metastatic LCT. All other mutations were detected in single cases (NBN, MTOR, BAP1, MEN1, 
and CREBBP) (Table 1). A single metastatic ovarian LCT had a BAP1 mutation and copy number 
amplifications of the NPM1, PCM1 and SS18 genes.  
 Copy number amplifications were detected in 8 out of 18 successfully tested cases (6 
testicular and two ovarian LCTs). The more prevalent CNAs included those affecting CCND3 
(two testicular) and genes in the fibroblast growth factor family: FGF3 (one primary ovarian), 
FGFR3 (one primary testicular and one primary ovarian) and FGFR4 (one metastatic testicular) 
(Table 1). 
Immuno-Oncology (I-O) Biomarkers 
 PD-L1 expression (threshold ≥1%) in the TC or IC was not seen in any of 15 tested 
testicular LCTs. All cases were MSI stable. A low tumor mutation burden (4-7 muts/Mb) 
characterized most of the testicular LCT except the peculiar metastatic case with a 
B4GALT5:TERT fusion and TOP1 and CCND3 amplifications that exhibited 11 muts/Mb (Table 1). 
 




 Our study represents the first comprehensive molecular study to examine potentially 
targetable molecular alterations in LCT including its malignant variants. One of the key findings 
in our study was that  TERT gene fusions were a major detected genetic alteration in malignant, 
metastatic Leydig cell tumors. This is a novel finding that had not been previously reported in 
sex-cord stromal tumors including LCT 3, 5, 8. In addition, all three described gene fusions 
affecting TERT gene have not been previously reported in the literature (review of the literature 
covered PubMed/MEDLINE and COSMIC database). TERT activity plays a central role in the 
unlimited self-renewal potential of cancer cells via telomerase activity that maintains telomere 
ends through addition of telomere repeats TTAGGG) 17. This mechanism is considered one of 
the hallmarks of cancer 18. Various genomic alterations including TERT promoter mutations, 
rearrangements, amplifications, fusions and promoter methylation have been well 
characterized across human cancers 19-21. Limited information of the therapeutic implications of 
TERT genomic alterations are currently available. One recent in vitro study conducted on acral 
melanoma cells revealed the cytotoxic effects of TERT inhibitors in melanoma cells harboring 
TERT genomic alterations 21.  
 The family of topoisomerase enzymes (TOP1 and TOPO2) are the key players in 
unwinding coiled DNA to facilitate the cell replication and transcription 22. Given their active 
role in DNA replication and transcription, several classes of drugs targeting TOP1 and TOPO2 
have been developed. One of these drugs is camptothecin against TOP1 whose derivatives 
irinotecan and topotecan have been widely used as cytotoxic drugs in a clinical setting. TOP1 
overexpression has been described in various cancers 15 whereas TOP1 gene amplification is a 
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much rarer event in cancers [the highest amplification rate (>10%) was reported in gall bladder, 
esophageal and gastroesophageal carcinomas] 15. Our study revealed a common (50-60%) TOP1 
expression in both primary and metastatic LCT while TOP1 gene amplification was observed in 
one metastatic case. This finding may be clinically relevant for malignant LCTs and provide a 
rationale for the treatment with camptothecin derivatives alone or combined with novel 
anticancer treatments such as antibody-drug conjugates (ADC) that contain irinotecan.  
 Hormone therapy with antiandrogens has been used therapeutically in prostate cancer 
patients 23. Some of the commonly used antiandrogens (e.g. bicalutamide) competitively inhibit 
ligand binding to the active AR. Our study also confirmed AR activity in LCTs without the 
presence of splice variant ARv7. In prostate cancer cells, ARv7 stems from aberrant mRNA 
splicing of AR exons 1–3, loss of exons 4–8, and inclusion of cryptic exon 3 (CE3) into the 
transcribed AR gene 24, 25. Consequently, the affected protein is constitutively active in the 
absence of androgens and facilitates the growth of prostate cancer in the presence of 
antiandrogens 26, 27. We found AR expression in 40% of metastatic LCT without the ARv7 splice 
variant, which indicates a potential for treatment with antiandrogens. 
 Immunotherapy with immune checkpoint inhibitors against PD-1/PD-L1 has markedly 
improved the treatment and outcome of multiple solid and hematological cancers (e.g. non-
small cell lung carcinoma, melanoma, renal cell carcinoma, urothelial bladder carcinoma, triple-
negative breast carcinoma, classical Hodgkin lymphoma). Several currently available predictive 
biomarkers (PD-L1 expression, high TMB, MSI-H status) with approved clinical utility have been 
explored in this study. In contrast to testicular germ cell tumors 28, 29, we found no PD-L1 
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expression in LCTs. With the exception of one case with high TMB (11 muts/Mb), all cases 
exhibited a low TMB, and all cases were MSI stable. Based on these results, it is unlikely that 
these patients would benefit from targeted therapy from immune checkpoint inhibitors. 
 There are several limitations of our study. The lack of matched primary sample analysis 
for cases with TERT fusion-positive metastases to determine if the fusions represent early 
events in more aggressive cancers or later events associated with metastasis. If the fusions are 
early events, patients with fusion-positive primary tumors could have increased surveillance.  In 
addition, the TERT promoter mutations, commonly observed in other malignancies (e.g., 
gliomas, bladder, thyroid cancers, melanoma), were not possible to examine in this study due 
to the lack of the gene promoter coverage in the NGS panel available at the time of study 30-33.  
Finally, there is lack of feedback information on the usefulness of molecular profiling in the 
treatment of metastatic LCT with potentially actionable findings detected in our cohort (e.g., 
over-expression of TOP1 and AR). 
 In conclusion, we identified for the first time TERT gene fusions as a main genetic 
alteration and several  potential therapeutic targets in malignant, metastatic Leydig cell 
tumorsincluding TOP1 and AR which may help guide decisions on chemo- and/or hormone 
therapy for selected individual patients.  
         
17 
 
CRediT author statement: JS and SV had full access to all the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis. 
Bozo Kruslin: Formal analysis, resources, writing – original draft preparation 
Zoran Gatalica: Conceptualization, data analysis, writing – original draft preparation, 
supervision 
Ondrej Hes: Formal analysis, resources 
Faruk Skenderi: Formal analysis, resources 
Markku Miettinen: Formal analysis, resources 
Elma Contreras: Formal analysis, validation 
Joanne Xiu: Formal analysis, validation 
Michelle Elis: Formal analysis, validation 
Elena Florento: Formal analysis, validation 
Semir Vranic: data analysis, writing – original draft preparation, supervision 
Jeffrey Swensen: Conceptualization, data analysis, writing – original draft preparation, 
supervision 
Data availability statement 
The data presented in the current study are available from the corresponding authors upon 
reasonable requests. 
  




1. Idrees MT, Ulbright TM, Oliva E, et al. The World Health Organization 2016 classification of 
testicular non-germ cell tumours: a review and update from the International Society of 
Urological Pathology Testis Consultation Panel. Histopathology. 2017;70:513-521. 
2. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: 
epidemiology and risk factors. Int J Womens Health. 2019;11:287-299. 
3. Fuller PJ, Leung D, Chu S. Genetics and genomics of ovarian sex cord-stromal tumors. Clin Genet. 
2017;91:285-291. 
4. de Kock L, Terzic T, McCluggage WG, et al. DICER1 Mutations Are Consistently Present in 
Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am J Surg Pathol. 
2017;41:1178-1187. 
5. Garg K, Karnezis AN, Rabban JT. Uncommon hereditary gynaecological tumour syndromes: 
pathological features in tumours that may predict risk for a germline mutation. Pathology. 
2018;50:238-256. 
6. McCluggage WG, Chong AL, de Kock L, Foulkes WD. Somatic tumour testing establishes that 
bilateral DICER1-associated ovarian Sertoli-Leydig cell tumours represent independent primary 
neoplasms. Histopathology. 2020;77:223-230. 
7. Kato N, Kusumi T, Kamataki A, Tsunoda R, Fukase M, Kurose A. DICER1 hotspot mutations in 
ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects. Hum Pathol. 
2017;59:41-47. 
8. Yuan Z, Huo X, Jiang D, et al. Clinical Characteristics and Mutation Analysis of Ovarian Sertoli-
Leydig Cell Tumors. Oncologist. 2020. 
9. Gargano SM, Senarathne W, Feldman R, et al. Novel therapeutic targets in salivary duct 
carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019;8:7322-7329. 
10. Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status 
determined by next-generation sequencing and compared with PD-L1 and tumor mutational 
burden in 11,348 patients. Cancer Med. 2018;7:746-756. 
11. Gatalica Z, Vranic S, Kruslin B, et al. Comparison of the biomarkers for targeted therapies in 
primary extra-mammary and mammary Paget's disease. Cancer Med. 2020;9:1441-1450. 
12. Vranic S, Palazzo J, Sanati S, et al. Potential Novel Therapy Targets in Neuroendocrine 
Carcinomas of the Breast. Clin Breast Cancer. 2019;19:131-136. 
13. Vranic S, Senarathne W, Stafford P, Poorman K, Pockaj BA, Gatalica Z. Biomarkers of Targeted 
Therapy and Immuno-Oncology in Cancers Metastatic to the Breast. Appl Immunohistochem Mol 
Morphol. 2019. 
14. Vranic S, Stafford P, Palazzo J, et al. Molecular Profiling of the Metaplastic Spindle Cell 
Carcinoma of the Breast Reveals Potentially Targetable Biomarkers. Clin Breast Cancer. 2020. 
15. Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R. Topoisomerase expression 
and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017;83:80-87. 
16. Marabelle A, Fakih MG, Lopez J, et al. Association of tumour mutational burden with outcomes 
in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. 
Annals of Oncology. 2019;30. 
17. Saretzki G. Telomeres, Telomerase and Ageing. Subcell Biochem. 2018;90:221-308. 
18. Leao R, Apolonio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P. Mechanisms of human 
telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci. 
2018;25:22. 
19. Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations 
in 31 cancer types. Nat Genet. 2017;49:349-357. 
         
19 
 
20. Chiba K, Lorbeer FK, Shain AH, et al. Mutations in the promoter of the telomerase gene TERT 
contribute to tumorigenesis by a two-step mechanism. Science. 2017;357:1416-1420. 
21. Liang WS, Hendricks W, Kiefer J, et al. Integrated genomic analyses reveal frequent TERT 
aberrations in acral melanoma. Genome Res. 2017;27:524-532. 
22. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new 
anticancer drugs. Ann Oncol. 1993;4:533-543. 
23. Reid P, Kantoff P, Oh W. Antiandrogens in prostate cancer. Invest New Drugs. 1999;17:271-284. 
24. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during 
prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 
2009;69:2305-2313. 
25. Zhu Y, Sharp A, Anderson CM, et al. Novel Junction-specific and Quantifiable In Situ Detection of 
AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 
2018;73:727-735. 
26. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-
dependent full-length androgen receptor and its splice variants in castration-resistant prostate 
cancer. Cancer Res. 2012;72:3457-3462. 
27. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants 
mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 
2013;73:483-489. 
28. Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor (PD-1) 
and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016;27:300-305. 
29. Fankhauser CD, Curioni-Fontecedro A, Allmann V, et al. Frequent PD-L1 expression in testicular 
germ cell tumors. Br J Cancer. 2015;113:411-413. 
30. Salgado C, Roelse C, Nell R, Gruis N, van Doorn R, van der Velden P. Interplay between TERT 
promoter mutations and methylation culminates in chromatin accessibility and TERT expression. 
PLoS One. 2020;15:e0231418. 
31. Lee DD, Komosa M, Nunes NM, Tabori U. DNA methylation of the TERT promoter and its impact 
on human cancer. Curr Opin Genet Dev. 2020;60:17-24. 
32. Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and 
telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38:6172-
6183. 
33. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. 













Biomarkers (number) Testis (n=27) 
Primary (n=20) Metastatic (n=7) 
Topo1α protein* (IHC) (n=17) 6/10 (60%) 4/7 (57%) 
Androgen receptor* (AR) 
(n=18) 
ARv7 (NGS and IHC) (n=18) 
10/13 (77%) 
All ARv7 negative (mRNA or protein) 
2/5 (40%)  
All ARv7 negative (mRNA or 
protein) 
 Genomic alterations 
 








Mutational profile (NGS)  
(n=15) 
CTNNB1 (2/10), NBN (1/10), MTOR (1/10), 






Copy number amplifications 
(NGS) (n=16) 
MDM2, TCF3, LRIG3, HMGA2, CYP2D6, 
ASPSCR1 (1 case) 
CDKN1B, DAXX, DDX5, PER1, VEGFB (1 case) 
MDM2, CDK4, CCND3, TFEB (1 case) 
GATA3, FGFR3, AKT2, TLX1, PIK3R2, MEF2B, 




TOP1, CCND3, MCL1 (1 
case) 
FGFR4, FLT4 (1 case) 
 I-O Biomarkers 
PD-L1 expression* (n=15) 0/10 (0%) 0/5 (0%) 
Tumor mutational burden 
(TMB) (n=7) 
4-7/Mb (n=4) 4-11/Mb (n=3) 
Microsatellite instability (MSI) 
(n=7) 




Primary (n=1) Metastatic (n=1) 
Topo1α protein* Not available Not available 
Androgen receptor (AR)* Not available Not available 
 Genomic alterations 
TERT gene fusions (NGS)** absent absent 
Mutational profile (NGS) none BAP1 
Copy number amplifications 
(NGS) 
FGF3, FGFR3 NPM1, PCM1, SS18 
 I-O Biomarkers 
PD-L1 expression* Not available Not available 
Tumor mutational burden 
(TMB) 
Not available 3 mutations/Mb 
Microsatellite instability (MSI) Not available Not available 
*Assessed by immunohistochemistry (IHC) 
**Archer® FusionPlex® assay; TERT promoter region was not covered by the analysis. 
TMB = Tumor mutational burden; MSI = Microsatellite instability; CNA = Copy number amplifications (by 
NGS); I-O = Immuno-Oncology. 
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Table 1. Molecular findings in the Leydig cell tumors cohort 
  






Figure 1. Hematoxylin and Eosin (H&E) slide of a metastatic Leydig cell tumor to the lung (A); 
the tumor cells were diffusely positive for Topo1 by immunohistochemistry (20x). 
  






Figure 2. TERT gene fusions detected in three metastatic (malignant) Leydig cell tumors of the 
testis. 
 
         
